Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Improving Outcomes of Tyrosine Kinase Inhibitors in Hepatocellular Carcinoma: New Data and Ongoing Trials
Lisha Mou, Xiaohe Tian, Bo Zhou, et al.
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 47

Showing 1-25 of 47 citing articles:

Lipid based nanoparticles as a novel treatment modality for hepatocellular carcinoma: a comprehensive review on targeting and recent advances
Khaled Y. Mahmoud, Shady A. Swidan, Mohamed A. El-Nabarawi, et al.
Journal of Nanobiotechnology (2022) Vol. 20, Iss. 1
Open Access | Times Cited: 60
Role of protein phosphorylation in cell signaling, disease, and the intervention therapy
Kun Pang, Wei Wang, Jiaxin Qin, et al.
MedComm (2022) Vol. 3, Iss. 4
Open Access | Times Cited: 56
Drug resistance mechanism of kinase inhibitors in the treatment of hepatocellular carcinoma
Lei Jiang, Luan Li, Yongzhuang Liu, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 28
Lenvatinib in hepatocellular carcinoma: Resistance mechanisms and strategies for improved efficacy
Y. Qin, Shisong Han, Yahan Yu, et al.
Liver International (2024) Vol. 44, Iss. 8, pp. 1808-1831
Closed Access | Times Cited: 7
Targeting the RAS upstream and downstream signaling pathway for Cancer treatment
Md. Arafat Hossain
European Journal of Pharmacology (2024) Vol. 979, pp. 176727-176727
Closed Access | Times Cited: 7
Survival strategies: How tumor hypoxia microenvironment orchestrates angiogenesis
Mengrui Yang, Yufeng Mu, Xiaoyun Yu, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 176, pp. 116783-116783
Open Access | Times Cited: 6
Modelling hepatocellular carcinoma microenvironment phenotype to evaluate drug efficacy
Sara Cherradi, Salomé Roux, Marie Dupuy, et al.
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access
Drug resistance in TKI therapy for hepatocellular carcinoma: mechanisms and strategies
Xue Jiang, Xiaoying Ge, Yueying Huang, et al.
Cancer Letters (2025), pp. 217472-217472
Closed Access
Research Status and Progress of Transcatheter Arterial Chemoembolization Combined with Transcatheter Arterial Chemoembolization in the Treatment of Primary Liver Cancer
秋吉 韦
Advances in Clinical Medicine (2025) Vol. 15, Iss. 01, pp. 1558-1566
Closed Access
Sporadic Medullary Thyroid Carcinoma: Towards a Precision Medicine
Antonio Matrone, Carla Gambale, Alessandro Prete, et al.
Frontiers in Endocrinology (2022) Vol. 13
Open Access | Times Cited: 29
Decreased Expression of Programmed Death Ligand-L1 by Seven in Absentia Homolog 2 in Cholangiocarcinoma Enhances T-Cell–Mediated Antitumor Activity
Hao Zheng, Wenjuan Zheng, Zhenguang Wang, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 28
Natural Products in Preventing Tumor Drug Resistance and Related Signaling Pathways
Chuansheng Yang, Zhikai Mai, Can Liu, et al.
Molecules (2022) Vol. 27, Iss. 11, pp. 3513-3513
Open Access | Times Cited: 26
Transarterial chemoembolization (TACE) plus tyrosine kinase inhibitors versus TACE in patients with hepatocellular carcinoma: a systematic review and meta-analysis
Ruihua Duan, Fen Gong, Yan Wang, et al.
World Journal of Surgical Oncology (2023) Vol. 21, Iss. 1
Open Access | Times Cited: 15
The use of machine learning modeling, virtual screening, molecular docking, and molecular dynamics simulations to identify potential VEGFR2 kinase inhibitors
Abbas Salimi, Jong Hyeon Lim, Jee Hwan Jang, et al.
Scientific Reports (2022) Vol. 12, Iss. 1
Open Access | Times Cited: 22
The action and resistance mechanisms of Lenvatinib in liver cancer
Anna Buttell, Wei Qiu
Molecular Carcinogenesis (2023) Vol. 62, Iss. 12, pp. 1918-1934
Open Access | Times Cited: 12
Camrelizumab, apatinib and hepatic artery infusion chemotherapy combined with microwave ablation for advanced hepatocellular carcinoma
Mengxuan Zuo, Chao An, Yu-Zhe Cao, et al.
World Journal of Gastrointestinal Oncology (2024) Vol. 16, Iss. 8, pp. 3481-3495
Open Access | Times Cited: 3
HCC: Evolving Role of Systemic Therapies as a Bridging Treatment to Liver Transplantation
Yacob Saleh, Taher Abu Hejleh, Maen Abdelrahim, et al.
(2024)
Open Access | Times Cited: 3
Biomarker discovery in hepatocellular carcinoma (HCC) for personalized treatment and enhanced prognosis
Baofa Yu, Wenxue Ma
Cytokine & Growth Factor Reviews (2024) Vol. 79, pp. 29-38
Closed Access | Times Cited: 3
RNF173 suppresses RAF/MEK/ERK signaling to regulate invasion and metastasis via GRB2 ubiquitination in Hepatocellular Carcinoma
Jie Zhou, Daoyuan Tu, Rui Peng, et al.
Cell Communication and Signaling (2023) Vol. 21, Iss. 1
Open Access | Times Cited: 9
PERK Inhibition by HC-5404 Sensitizes Renal Cell Carcinoma Tumor Models to Antiangiogenic Tyrosine Kinase Inhibitors
Michael E. Stokes, Verónica Calvo, Sho Fujisawa, et al.
Clinical Cancer Research (2023) Vol. 29, Iss. 23, pp. 4870-4882
Open Access | Times Cited: 8
Evaluation of the cytotoxic activity of sorafenib‐loaded camel milk casein nanoparticles against hepatocarcinoma cells
Aastha Mittal, Neelam Mahala, Nikhil Hanamant Dhanawade, et al.
Biotechnology Journal (2024) Vol. 19, Iss. 3
Closed Access | Times Cited: 2
Hepatocellular Carcinoma: The Evolving Role of Systemic Therapies as a Bridging Treatment to Liver Transplantation
Yacob Saleh, Taher Abu Hejleh, Maen Abdelrahim, et al.
Cancers (2024) Vol. 16, Iss. 11, pp. 2081-2081
Open Access | Times Cited: 2
New Opportunities to Individualize Frontline Therapy in Advanced Stages of Hepatocellular Carcinoma
John D. Gordan, Bridget P. Keenan, Huat Chye Lim, et al.
Drugs (2023) Vol. 83, Iss. 12, pp. 1091-1109
Closed Access | Times Cited: 6
Role of pelitinib in the regulation of migration and invasion of hepatocellular carcinoma cells via inhibition of Twist1
Sewoong Lee, Eunjeong Kang, Unju Lee, et al.
BMC Cancer (2023) Vol. 23, Iss. 1
Open Access | Times Cited: 6
Efficacy and safety of transarterial chemoembolization plus lenvatinib with or without programmed death-1 inhibitors in the treatment of unresectable hepatocellular carcinoma: a systematic review and meta-analysis
Junning Liu, Wei Song, Linfeng Yang, et al.
Journal of Cancer Research and Clinical Oncology (2023) Vol. 149, Iss. 15, pp. 14451-14461
Closed Access | Times Cited: 6
Page 1 - Next Page

Scroll to top